AKBA - Akebia - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

366.6M

Cash

41.96M

Avg Qtr Burn

-6.32M

Short % of Float

9.16%

Insider Ownership

2.14%

Institutional Own.

27.06%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Auryxia (ferric citrate) Details Chronic kidney disease, Anemia, Kidney disease, Hyperphosphatemia	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vafseo™ (Vadadustat) Details Chronic kidney disease, Anemia, Kidney disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.